543500 logo

Evoq Remedies BSE:543500 Stock Report

Last Price

₹7.07

Market Cap

₹176.0m

7D

1.0%

1Y

-46.0%

Updated

30 Jan, 2025

Data

Company Financials

Evoq Remedies Limited

BSE:543500 Stock Report

Market Cap: ₹176.0m

543500 Stock Overview

Engages in the marketing, trading, and distribution of pharmaceutical formulations in India. More details

543500 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance3/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Evoq Remedies Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Evoq Remedies
Historical stock prices
Current Share Price₹7.07
52 Week High₹15.39
52 Week Low₹6.72
Beta0.55
1 Month Change-9.36%
3 Month Change-16.33%
1 Year Change-46.03%
3 Year Changen/a
5 Year Changen/a
Change since IPO-70.23%

Recent News & Updates

Recent updates

Shareholder Returns

543500IN PharmaceuticalsIN Market
7D1.0%-3.4%-1.4%
1Y-46.0%18.6%5.8%

Return vs Industry: 543500 underperformed the Indian Pharmaceuticals industry which returned 18.6% over the past year.

Return vs Market: 543500 underperformed the Indian Market which returned 5.8% over the past year.

Price Volatility

Is 543500's price volatile compared to industry and market?
543500 volatility
543500 Average Weekly Movement7.5%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement6.3%
10% most volatile stocks in IN Market9.0%
10% least volatile stocks in IN Market4.3%

Stable Share Price: 543500 has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: 543500's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2010n/aBhumishth Patelwww.evoqremedies.com

Evoq Remedies Limited engages in the marketing, trading, and distribution of pharmaceutical formulations in India. The company trades in sweeteners, such as acesulfame potassium, aspartem, dextrose, erythritol, euro vanillin powder, malodextrin, miglitol, etc.; amino acids, such as L- alanine, L-arginine, L-aspartic acid, L-carnitine, L-cystine, L-glutamic acids, L-glutamine, L-glutathione, L-glycine, L-isoleucine, LL-trytophan, L-tyrosine, L-lysine, N-acetyl, and L-andystine; excipients, which include aspartem, bronopol, cross carmellous sodium, cross povidone, ethyl olliate, hard peraffin, hpmc all grades, light liquid paraffin, mannitol, menthol crystal, etc.; neutraceuticals; and opthalamics, which include atropine sulphate, bimatoprost, brimonidine, bromfenac, cyclopentolate, dorzolamide fluoromethelone, flurbiprofen, gatifloxacin, ketorolac tromethamine, latanoprost, natamycin, nepafenac, olopatadine, sulphacetamide sodium, timolol meleate, etc. It also offers ointments, such as adapalene, allantoin, avobenzone, azealic acid, calamine, chlorocresol, cetrimide, clindamycin phoshphate, clobetasol propionate, clotrimazole, cream base, cyclosporine, fluocinolol acetonide, fusidic acid, gamabenzene, gentamycin sulphate, halobetasol, hydroquinone, etc.; and oncology drugs, such as abiraterone acetate, alfuzosin, anastrazole, axitinib, azacitidine, bicalutamide, bleomycin, bosutinib, busualphan, capcitabine, carboplatin, cisplatin, etc. It also offers anti-biotic drugs, anti-malarial drugs, anti-allergic, anti cold drugs, analgesic/ anti-pyretic, anti inflammatory drugs, dermatology products, cerebral activator drugs, neurological drugs, gastro intestinal drugs, steroids, gynecology drugs, calcium, multivitamins, anti-oxidants, and injections. In addition, it provides vitamins, dairy and spice products, sterile, active pharmaceutical ingredients, and veterinary feed products.

Evoq Remedies Limited Fundamentals Summary

How do Evoq Remedies's earnings and revenue compare to its market cap?
543500 fundamental statistics
Market cap₹176.04m
Earnings (TTM)₹4.52m
Revenue (TTM)₹63.09m

38.9x

P/E Ratio

2.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
543500 income statement (TTM)
Revenue₹63.09m
Cost of Revenue₹15.66m
Gross Profit₹47.43m
Other Expenses₹42.91m
Earnings₹4.52m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.18
Gross Margin75.18%
Net Profit Margin7.17%
Debt/Equity Ratio16.8%

How did 543500 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 01:17
End of Day Share Price 2025/01/30 00:00
Earnings2024/03/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Evoq Remedies Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution